SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

Carlos López; Mariona Calvo; Juan Carlos Cámara; Beatriz García-Paredes; Carlos Gómez-Martín; Ana María López; Roberto Pazo-Cid; Javier Sastre; Ricardo Yayá; Jaime Feliú

doi:10.1007/s12094-024-03568-4

June 24, 2024Clinical & Translational OncologyOpen Access

SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

View Full Paper

Ask AI

Bookmark

Share

Key Points

Surgery remains the sole curative intervention for hepatocellular carcinoma, while local and systemic therapies extend overall survival when surgical resection is clinically unsuitable.
Clinical guideline recommendations endorse regular abdominal ultrasound screening alongside the standardized BCLC staging system to establish precise tumor staging and guide therapy.
Systemic therapy is specifically advised for advanced stage disease in patients presenting with preserved liver function categorized under Child-Pugh class A and ECOG performance status.

Implication

Clinical guideline highlights multimodal management pathways for hepatocellular carcinoma, suggesting personalized treatment and surveillance protocols to optimize patient survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

López et al. (2024) studied this question.

synapsesocial.com/papers/68e637f1b6db6435875c9903 https://doi.org/10.1007/s12094-024-03568-4

View Full Paper

Ask AI

Bookmark

Share

SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

Key Points

Implication

Discussion

Cite This Study

SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

Key Points

Implication

Discussion

Cite This Study

Keep reading

Keep reading